争议事件
以下收录公开来源中与该品牌相关的争议事件。列出一条并不表示过错已经证实。
返回词条共 7 条
2023
2022
Teva就德州阿片类药物诉讼达成和解
和解
梯瓦制药工业有限公司达成价值2.25亿美元的和解，以解决德州提出的关于其通过不当营销成瘾性止痛药助长阿片类药物流行的指控。报道指出，梯瓦在和解中未承认不当行为。该事件于2022年2月7日被报道。
当事方说明的目的. 该和解旨在解决德州提出的相关索赔。
来源摘录
Teva Pharmaceutical Industries has reached a settlement worth $225 million to resolve claims the drugmaker fueled an opioid epidemic in Texas by improperly marketing addictive pain medications, the state's attorney general said on Monday, according to Reuters.
Teva did not admit wrongdoing as part of Monday's settlement, according to Reuters.
2022
Teva 就投资者价格操纵诉讼达成和解
和解
Teva 就美国投资者针对涉嫌价格操纵提起的集体诉讼达成和解，同意支付 4.2 亿美元，但不承认有不当行为。Teva 否认相关指控；该诉讼是在美国当局调查仿制药行业涉嫌价格操纵后提起的。
品牌回应
否认 — Teva
Teva will pay $420 million, without admitting wrongdoing, and it denies the claims.
来源摘录
Teva will pay $420 million, without admitting wrongdoing, and it denies the claims.
Now, Teva has also settled a class action filed against it by investors in the US over the price fixing affair in which the company was allegedly involved.
Teva Pharmaceutical Industries Ltd. has agreed to pay $420 million to settle shareholder litigation alleging the company hid an anti-competitive scheme to fix the price of generic drugs.
2021
Mylan 就涉嫌限制 Copaxone 竞争起诉 Teva
提起诉讼
Mylan Pharmaceuticals 在联邦法院起诉 Teva，指控其采取手段延迟多发性硬化症药物 Copaxone 面临的竞争。报道未称这些指控已获法院认定，并指出 Teva 尚未回应。
来源摘录
With the suit just filed, Teva has not yet had time to file a response.
Mylan alleges that Teva used various tactics to delay competition and maintain its monopoly on Copaxone, costing the U.S. healthcare system billions in excess spending.
Morgantown-based Mylan Pharmaceuticals—not its parent Viatris—filed the suit in U.S. District Court for the District of New Jersey against Teva and several of its subsidiaries.
2020
美国政府就Copaxone涉嫌回扣起诉Teva
提起诉讼
美国司法部依据《联邦虚假申报法》起诉梯瓦制药工业有限公司。诉讼指称，Teva旗下公司通过据称独立的基金会为Copaxone患者支付Medicare共付额，违反《反回扣法》。这些指控未被表述为法院认定。
美国司法部依据《联邦虚假申报法》起诉Teva。诉讼指称，Teva旗下公司通过据称独立的基金会为Copaxone患者支付Medicare共付额，违反《反回扣法》；报道未称这是法院认定。
来源摘录
The lawsuit claims that Teva paid two third-party foundations more than $300 million to cover Medicare co-payment obligations of Copaxone patients.
According to the lawsuit, Teva Pharmaceuticals USA Inc. and Teva Neuroscience Inc. illegally paid the Medicare co-pays for their multiple sclerosis product, Copaxone, through purportedly independent foundations that the companies used as conduits in violation of the Anti-Kickback Statute.
Teva Pharmaceutical Industries Ltd. (TEVA) has been sued by the U.S. Department of Justice under the Federal False Claims Act.
2020
欧盟因仿制莫达非尼延迟协议对梯瓦处以罚款
罚款或处罚
在2020年记录的一起争议事件中，欧盟对梯瓦制药工业有限公司处以罚款。欧盟委员会表示，梯瓦与Cephalon达成协议，使价格较低的莫达非尼仿制药无法进入市场，从而违反了欧盟反垄断规则。欧盟委员会认为，该协议阻止了低价莫达非尼仿制药进入市场，违反了欧盟竞争规则。欧盟据此对梯瓦处以罚款。该事件涉及欧盟就仿制莫达非尼相关协议作出的反垄断认定及处罚。
来源摘录
The European Commission said Teva was in breach of EU antitrust rules after it effectively agreed with drug-maker Cephalon, a company it now owns, to keep the cheaper drug off of the market.
European Union regulators on Thursday fined Israeli drug-maker Teva for colluding to delay a cheaper generic version of modafinil, a blockbuster sleep disorder drug, AFP reports.
2019